TA-35 closes 0.5 percent lower as ICL weighs
Published on 10/12/2026 at 22:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- TA-35 closed at 4,041 points on October 12, down 20 points or 0.5 percent.
- Twenty-eight index stocks fell while eight rose, keeping breadth negative.
- Teva gained 4.8 percent, while ICL fell 4.1 percent.
- Israel's September consumer price index is due on October 15, with a 0.3 percent decline forecast.
TA-35 closed at 4,041 points on October 12, down 20 points or 0.5 percent, as Bizportal reported. Decliners outnumbered advancers 28 to 8.
Teva rose 4.8 percent after Friday's FDA approval for its monthly schizophrenia injection, while ICL fell 4.1 percent. The index finished below its 4,062-point base level after trading between 4,028 and 4,085 points.
Why did TA-35 finish lower despite Teva's advance?
Biomed, real estate and technology stocks led the stronger sectors, according to Investing.com. That strength did not offset losses across much of the index.
Teva's move followed the company's FDA approval announced before Monday's session. The approval concerns WELTRUZA, a monthly treatment for schizophrenia, as Bizportal reported.
Winners and losers in TA-35
- Palo Alto Networks up 5.3 percent, according to Bizportal
- Teva up 4.8 percent after the FDA decision, Bizportal reported
- ICL down 4.1 percent, according to Bizportal
- Bezeq down 3.6 percent, according to Bizportal
TA-35 carries a positive year-to-date balance
TA-35 was up 11.9 percent for the year through October 12, while its monthly performance stood at down 3.4 percent. The daily decline extended a weak October stretch.
What comes next for TA-35
October 15, 2026: Israel's September consumer price index is due, with forecasts for a 0.3 percent monthly decline, as Bizportal reported. The next Bank of Israel rate decision is scheduled for October 21.
